Plaque Psoriasis

FDA clears once-daily icotrokinra for moderate-to-severe plaque psoriasis in adults and teens.

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

This Q&A with Neal Bhatia, MD, features a discussion conducted regarding GLP-1 use in patients with psoriasis and obesity or overweight.

In this February review of the most significant developments in dermatology, the month’s most notable coverage of disease states such as psoriasis and atopic dermatitis is highlighted.

Neal Bhatia, MD, speaks on new data on ixekizumab and tirzepatide for weight loss and psoriasis, as well as the implications of these data regarding GLP-1 use.

In this interview, Neal Bhatia, MD, highlights several key points about treating psoriasis and obesity via ixekizumab and tirzepatide.

Vanda Pharmaceuticals announced the FDA's acceptance of imsidolimab's Biologics License Application for the treatment of GPP.

HCPLive speaks with Mark Lebwohl, MD, about recent data on those with psoriasis and obesity or overweight treated with ixekizumab (Taltz) and tirzepatide (Zepbound).

An audio recap of the top 5 stories in healthcare news from the week of 02/15-02/21.

This interview segment highlights additional points on bimekizumab and psoriasis related to patient-reported outcomes (PROs) in the 3 year BE RADIANT study.

In this segment of his interview, Vender highlighted his own views on the significance of BE RADIANT trial findings on bimekizumab for psoriasis.

This interview with Vender highlights recent findings on patient-reported outcomes (PROs) in patients in the BE RADIANT trial with psoriasis.

In the phase 3b BE RADIANT trial and its open-label extension, bimekizumab treatment led to durable improvements in patient-reported outcomes over 3 years.

These data, released by Lilly, suggest ixekizumab (Taltz) and tirzepatide (Zepbound) are more effective when used together versus ixekizumab monotherapy.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

Eichenfield speaks in this interview about several key takeaways drawn from her master class in pediatric dermatology at Maui Derm Hawaii.

This Q&A interview with Philip Mease, MD, highlights his contribution to the ‘Psoriasis Update 2026’ talk given at the 2026 Maui Derm Hawaii meeting.

This interview at Maui Derm 2026 highlights notable takeaways regarding psoriasis treatment strategies and emerging therapies.

In this analysis presented at Maui Derm, indirect comparisons were made between risankizumab and icotrokinra in patients with psoriasis.

The Maui Derm Hawaii 2026 conference featured a poster presentation highlighting recent phase 3 findings on risankizumab in pediatric patients.

The safety and efficacy of risankizumab versus deucravacitinib were evaluated among patients with moderate psoriasis and no prior biologic use.

This Q&A interview with Dawn Eichenfield, MD, PhD, highlights notable takeaways from her session at Maui Derm Hawaii titled ‘Pediatric Dermatology 2026.’

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

This interview at the 2026 Maui Derm Hawaii meeting features a discussion of new and emerging therapies in psoriasis, including icotrokinra.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.